Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MBX Biosciences, Inc.MBX · Entity 4247 | Director · President & CEO | May 06, 2026 | May 08, 2026 |
| MetaVia Inc.GEMP · Entity 7947 | Director | January 29, 2018 | January 30, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MBX Biosciences, Inc.
Report date May 06, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 727,667 |
Reported balance
After 2026-05-06 transaction · row 1
1 source rowRow 1 · 2026-05-06 · Sale · Disposed 607 · Balance 727,667 F1: The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company. F2: The price reported in Column 4 is a weighted average price. These shares were sold on an aggregrate basis for all Company participants, at prices ranging from $29.23 to $29.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregrate number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 486,777 |
Reported balance
Holding disclosure · report date 2026-05-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 486,777 F3: Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company.
F2: The price reported in Column 4 is a weighted average price. These shares were sold on an aggregrate basis for all Company participants, at prices ranging from $29.23 to $29.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregrate number of shares sold at each separate price within the range set forth in this footnote.
F3: Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
MetaVia Inc.
Report date January 29, 2018 · Filed January 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2028-01-28 | Direct | 10,800 |
Reported balance
After 2018-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-29 · Grant · Acquired 10,800 · Balance 10,800 F1: The option vests in a series of 12 successive equal monthly installments on the last day of each month, commencing on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in a series of 12 successive equal monthly installments on the last day of each month, commencing on the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2026 Filed May 8, 2026 20:00 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | SaleCommon Stock | 607 | $29.54 | $17,930.78 |
DisclosureSEC source: 0001193125-26-214574 · ownership.xml · nonDerivative · entry 1 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 727,667 F1 · kind: The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold on an aggregrate basis for all Company participants, at prices ranging from $29.23 to $29.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregrate number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 12:02 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | PurchaseCommon Stock | 18,500 | $28.41 | $525,662.70 |
DisclosureSEC source: 0001193125-26-107268 · ownership.xml · nonDerivative · entry 2 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 486,777 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.28 to $28.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:07 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | Exercise / conversionStock option (right to buy) · Derivative | 28,768 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-082562 · ownership.xml · derivative · entry 3 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,668 Underlying: Common Stock · 28,768 shares Expires 2034-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares underlying this option vested and became exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:07 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | Exercise / conversionCommon Stock | 28,768 | $16.00 | $460,288.00 |
DisclosureSEC source: 0001193125-26-082562 · ownership.xml · nonDerivative · entry 1 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:16 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock option (right to buy) · Derivative | 164,500 | $0.00 Strike: $39.07 | $0.00 |
DisclosureSEC source: 0001193125-26-035582 · ownership.xml · derivative · entry 3 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,500 Underlying: Common Stock · 164,500 shares Expires 2036-02-02 F3 · derivative.exercise_date: The shares underlying this option vest and become exercisable in forty eight (48) equal monthly installments, beginning on March 2, 2026, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:16 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantCommon Stock | 35,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-035582 · ownership.xml · nonDerivative · entry 1 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 699,506 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs will vest over a four (4) year period in equal quarterly installments, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| October 24, 2025 Filed Oct 28, 2025 12:03 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | Exercise / conversionStock option (right to buy) · Derivative | 182,859 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001193125-25-252404 · ownership.xml · derivative · entry 3 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,708 Underlying: Common Stock · 182,859 shares Expires 2032-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares underlying this option vest in substantially equal monthly installments on each monthly anniversary of November 7, 2022, subject to the Reporting Person's continued service on each such vesting date, until the option vests in full on November 7, 2026. The shares underlying this option became exercisable in full on November 7, 2022, pursuant to an early-exercise provision, subject to an Issuer right of repurchase. Read SEC document |
| October 24, 2025 Filed Oct 28, 2025 12:03 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | Exercise / conversionCommon Stock | 182,859 | $3.25 | $594,291.75 |
DisclosureSEC source: 0001193125-25-252404 · ownership.xml · nonDerivative · entry 1 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 664,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2025 Filed Oct 21, 2025 21:43 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | PurchaseCommon Stock | 20,000 | $13.64 | $272,790.00 |
DisclosureSEC source: 0001193125-25-245411 · ownership.xml · nonDerivative · entry 2 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 468,277 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.60 to $13.6399, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:17 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | PurchaseCommon Stock | 50,000 | $10.69 | $534,500.00 |
DisclosureSEC source: 0000950170-25-014494 · ownership.xml · nonDerivative · entry 1 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 448,277 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.60 to $10.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:17 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock Option (Right to Buy) · Derivative | 243,000 | $0.00 Strike: $10.49 | $0.00 |
DisclosureSEC source: 0000950170-25-014494 · ownership.xml · derivative · entry 3 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,000 Underlying: Common Stock · 243,000 shares Expires 2035-02-03 F3 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on February 3, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:07 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionSeries C Convertible Preferred Stock · Derivative | 970,873 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107527 · ownership.xml · derivative · entry 7 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 80,757 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:07 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionSeries B Convertible Preferred Stock · Derivative | 76,969 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107527 · ownership.xml · derivative · entry 6 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 6,402 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:07 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,396,762 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107527 · ownership.xml · derivative · entry 5 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 116,182 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:07 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionSeries A Convertible Preferred Stock · Derivative | 345,705 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107527 · ownership.xml · derivative · entry 4 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 28,755 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:07 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionSeries A Convertible Preferred Stock · Derivative | 2,015,681 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107527 · ownership.xml · derivative · entry 3 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 167,664 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:07 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionCommon Stock | 115,914 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107527 · ownership.xml · nonDerivative · entry 2 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 398,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:07 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionCommon Stock | 283,846 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107527 · ownership.xml · nonDerivative · entry 1 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 481,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:06 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock Option (Right to Buy) · Derivative | 120,436 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-106441 · ownership.xml · derivative · entry 1 Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,436 Underlying: Common Stock · 120,436 shares Expires 2034-09-11 F1 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 29, 2018 Filed Jan 30, 2018 21:44 UTC | MetaVia Inc. GEMP · Entity 7947 | GrantStock Option (right to buy) · Derivative | 10,800 | $0.00 Strike: $10.44 | $0.00 |
DisclosureSEC source: 0001596771-18-000014 · primary_doc.xml · derivative · entry 1 Hawryluk P. Kent · CIK 0001673991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2028-01-28 F1 · derivative.exercise_date: The option vests in a series of 12 successive equal monthly installments on the last day of each month, commencing on the grant date. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 21:46 UTC | MetaVia Inc. GEMP · Entity 7947 | PurchaseWarrant to Purchase Common Stock · Derivative | 18,750 | $9.47 Strike: $10.40 | $177,562.50 |
DisclosureSEC source: 0001596771-17-000021 · primary_doc.xml · derivative · entry 3 Hawryluk P. Kent · CIK 0001673991 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the P. Kent Hawryluk Revocable Trust Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2022-03-15 F1 · shares: The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017. F1 · price: The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017. F2 · ownership.nature: These shares are indirectly owned by the reporting person as trustee of the P. Kent Hawryluk Revocable Trust. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 21:46 UTC | MetaVia Inc. GEMP · Entity 7947 | PurchaseCommon Stock | 25,000 | $9.47 | $236,750.00 |
DisclosureSEC source: 0001596771-17-000021 · primary_doc.xml · nonDerivative · entry 1 Hawryluk P. Kent · CIK 0001673991 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the P. Kent Hawryluk Revocable Trust Disclosed balance after: 81,889 F1 · shares: The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017. F1 · price: The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017. F2 · ownership.nature: These shares are indirectly owned by the reporting person as trustee of the P. Kent Hawryluk Revocable Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.